CORAL SPRINGS, FL--(Marketwired - Dec 2, 2013) - Nutra Pharma Corp. (
In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin® to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. TCN has now created a stand-alone opportunity for distributors under the name MyNyloxin. The launch will take place throughout the month of December and will include webinars, internet, radio and television advertising.
"The Nyloxin products continue to represent a wonderful opportunity for our distributors," commented Dalton Johnson, CEO of MyNyloxin. "The new focus of the Company is solely on the Nyloxin opportunity for our Distributors. These are pain-relievers and anti-inflammatory drugs that have provided great results with almost no risk of side effects. With the rollout through the next several months, our goal is to achieve significant sales through our distributors that will provide continuity as they use and order the product every month," he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain. The Company recently announced the beginning of marketing efforts by New Vitality for the Direct Response and retail marketing of Nyloxin. New Vitality's first Nyloxin television commercials are scheduled to begin shortly.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The agreement with MyNyloxin should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
- Health Care Industry
- Investment & Company Information